National Institute of Allergy and Infectious Diseases (NIAID): Granulomatosis with Polyangiitis trials
The registry lists 12 Granulomatosis with Polyangiitis studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 1 3Phase 2 6Phase 3 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic PolyangiitisCompletedNCT00104299Phase 2/3Results posted
- An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard TherapiesCompletedNCT00072592Phase 1
- Daclizumab to Treat Wegener's GranulomatosisCompletedNCT00040248Phase 2
- Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis SyndromesCompletedNCT00004567Phase 2
- Etanercept to Treat Wegener's GranulomatosisCompletedNCT00001901Phase 2
- Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory ConditionsCompletedNCT00001764Phase 1
- Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's GranulomatosisCompletedNCT00001761Phase 1
- Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission TomographyCompletedNCT00001759
- Analysis of Bronchial Tissue and Fluid in Patients With Wegener's GranulomatosisCompletedNCT00001541
- Cyclophosphamide and Prednisone Followed by Methotrexate To Treat VasculitidesCompletedNCT00001473
- Steroids and Methotrexate to Treat Systemic VasculitisCompletedNCT00001256Phase 2
- Treatment of Wegener's Granulomatosis With CyclophosphamideCompletedNCT00001155Phase 2